97643-35-1

Usage

Uses

Used in Pharmaceutical Industry:
5(S),6(R),15(S)-TRIHETE METHYL ESTER is used as a prodrug formulation for enhancing the lipid solubility and bioavailability of LXA4, allowing for better absorption and distribution in the body. This leads to improved therapeutic outcomes in various inflammatory and immune-related conditions.
Used in Inflammatory Disease Treatment:
5(S),6(R),15(S)-TRIHETE METHYL ESTER is used as an anti-inflammatory agent for the treatment of various inflammatory diseases. Its ability to modulate leukocyte activation, chemotaxis, and other immune functions helps in reducing inflammation and promoting tissue repair.
Used in Immune Regulation:
5(S),6(R),15(S)-TRIHETE METHYL ESTER is used as an immune modulator to regulate the immune response in various conditions. Its effects on natural killer cell inhibition and monocyte migration and adhesion contribute to the fine-tuning of the immune system and prevention of excessive immune reactions.
Used in Drug Delivery Systems:
5(S),6(R),15(S)-TRIHETE METHYL ESTER can be incorporated into drug delivery systems to improve the targeting and efficacy of LXA4 in specific tissues and cells. This can lead to better treatment outcomes and reduced side effects in various therapeutic applications.

Upstream product

• 78606-80-1 5(S), 6(R), 7-trihydroxyheptanoic acid methyl ester 
• 76745-15-8 4-((4S,5R)-5-Hydroxymethyl-2,2-dimethyl-[1,3]dioxolan-4-yl)-butyric acid methyl ester 
• 102354-82-5 methyl 4-(5-formyl-2,2-dimethyl-1,3-dioxolan-4-yl)butanoate 
• 97643-30-6 (S)-5-{(2S,3S)-3-[(1Z,4Z,6E)-(S)-8-(tert-Butyl-dimethyl-silanyloxy)-trideca-1,4,6-trienyl]-oxiranyl}-5-hydroxy-pentanoic acid methyl ester 
• 97579-45-8 (7E,9E,11Z,13E)-(5R,6R,15R)-15-(tert-Butyl-dimethyl-silanyloxy)-5,6-bis-trimethylsilanyloxy-icosa-7,9,11,13-tetraenoic acid methyl ester 
• 97579-44-7 5-{3-[(1Z,4Z,6E)-(S)-8-(tert-Butyl-dimethyl-silanyloxy)-trideca-1,4,6-trienyl]-oxiranyl}-5-hydroxy-pentanoic acid methyl ester 
• 97579-42-5 (6E,8Z,11Z,13E)-(S)-15-(tert-Butyl-dimethyl-silanyloxy)-5-hydroxy-icosa-6,8,11,13-tetraenoic acid methyl ester 
• 97643-28-2 (5Z,8Z,11Z,13E)-(S)-15-(tert-Butyl-dimethyl-silanyloxy)-icosa-5,8,11,13-tetraenoic acid methyl ester 
• 97579-38-9 (5Z,8Z,11Z,13E)-(S)-15-(tert-Butyl-dimethyl-silanyloxy)-icosa-5,8,11,13-tetraenoic acid 
• 70946-44-0 (5Z,8Z,11Z,13E,15S)-15-hydroxy-5,8,11,13-eicosatetraenoic acid methyl ester 
• 97579-43-6 (6E,8Z,11Z,13E)-(5S,15S)-15-(tert-Butyl-dimethyl-silanyloxy)-5-hydroxy-icosa-6,8,11,13-tetraenoic acid methyl ester 
• 97579-41-4 (S)-6-[(1E,3Z,6Z,8E)-(S)-10-(tert-Butyl-dimethyl-silanyloxy)-pentadeca-1,3,6,8-tetraenyl]-tetrahydro-pyran-2-one 
• 127251-13-2 (S)-6-((1E,3Z,6Z,8E)-(S)-10-Hydroxy-pentadeca-1,3,6,8-tetraenyl)-tetrahydro-pyran-2-one 
• 506-32-1 all cis 5,8,11,14-eicosatetraenoic acid 

Downstream Products

• 89663-86-5 lipoxin A₄ 
• 94292-80-5 6S-Lipoxin A₄ 
• 94292-86-1 lipoxin A4 

Relevant academic research and scientific papers

Stereoselective total synthesis of 5(S), 6(R), 15(S)-trihydroxy-7(E), 9(E), 11(Z), 13(E)-eicosatetraenoic acid (Lipoxin A)

A stereoselective synthesis of the title compound from D-xylose using zinc mediated deoxygenation of 4-hydroxy-2-butenoic acid moiety and base induced double elimination of 4,5-epoxy allyl chloride as key steps is described.

A SIMPLE AND EFFICIENT SYNTHESIS OF (7E,9E,11Z,13E)-(5S,6R,15S)-TRIHYDROXYEICOSATETRAENOIC ACID (6R-LIPOXIN A)

A practical seven-step synthetic route to 6R-lipoxin A from arachidonic acid is described which makes this biologically interesting eicosanoid easily available.

SIMPLE SYNTHESIS AND ASSIGNMENT OF STEREOCHEMISTRY OF LIPOXIN A

A synthesis of lipoxin A, a recently descovered biologically active eicosanoid, and the assignment of stereoformula 1 is reported herein.

SYNTHESIS OF LIPOXINS: TOTAL SYNTHESIS OF CONJUGATED TRIHYDROXY EICOSATETRAENOIC ACIDS

The first synthesis of a conjugated trihydroxy eicosatetraenoic acid, a possible structure for Lipoxin A is described.A biomimetic approach was utilized.